News und Analysen
Premier, Inc. Reports Fiscal 2020 Fourth-Quarter and Full-Year Results
Premier, Inc. (NASDAQ: PINC) today reported financial results for the fiscal year (FY) 2020 fourth quarter and full year ended June 30, 2020.
All results presented in this press release reflect
Ipsen to Present Results From MOVE, the First Global Phase III Trial in Fibrodysplasia Ossificans Progressiva (FOP), at ASBMR 2020 Annual Meeting
Ipsen (Euronext: IPN; ADR: IPSEY) today announced results from the MOVE trial, the first and only multicenter Phase III study in fibrodysplasia ossificans progressiva (FOP), to be presented during
Antibe Therapeutics Reports Q1 2021 Interim Financial and Operating Results
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Monday, August 24 for the fiscal quarter ended June 30, 2020. The
Navidea Biopharmaceuticals to Present at The LD 500 Virtual Investor Conference
Navidea Biopharmaceuticals, Inc. (NYSE American:NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced
QIAGEN führt einfach zu bedienenden, digitalen Test zum Nachweis von SARS-CoV-2-Antikörpern nach beantragter FDA-Notfallzulassung auf dem US-Markt ein
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute die Einführung seines neuen Access Anti-SARS-CoV-2 Total Tests auf dem US-Markt bekannt. Hierbei handelt es sich um einen einfach
QIAGEN to Launch Easy-to-Use Digital Test in the U.S. for Rapid Detection of SARS-CoV-2 Antibodies Following FDA Emergency Use Authorization
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. launch of the new Access Anti-SARS-CoV-2 Total test, an easy-to-use digital test done on a portable device that
QIAGEN announces new Chairman of Supervisory Board
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced today a transition in the leadership of its Supervisory Board after an extraordinary meeting of the Supervisory Board and
QIAGEN gibt neuen Aufsichtsratsvorsitzenden bekannt
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute im Anschluss an eine außerordentliche Sitzung des Aufsichtsrats und des Vorstands einen Wechsel im Vorsitz des Aufsichtsrats
Pfizer and BioNTech Share Positive Early Data on Lead mRNA Vaccine Candidate BNT162b2 Against COVID-19
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today shared additional Phase 1 safety and immunogenicity data from their ongoing U.S. study of the BNT162 mRNA-based vaccine program against
Antibe Therapeutics Announces Results of Annual and Special Meeting
Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) is pleased to announce the results of its annual and special meeting held earlier today. All resolutions outlined in the management information
Quidel Concludes Sofia® SARS Antigen Investigation From Vermont
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has
EnWave to Report Third Quarter Fiscal 2020 Financial Results on August 27, 2020 and Provides NutraDried Update
Vancouver, B.C., August 20th, 2020 - EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the "Company" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/ ), a global
EnWave berichtet das dritte Quartal des Geschäftsjahres 2020 am 27. August 2020 und gibt Update zu NutraDried
Vancouver, B.C., 20. August 2020 - Die EnWave Corporation (TSX-V:ENW | FSE:E4U) ("EnWave", oder das "Unternehmen" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/ ), ein
Quidel to Update Packaging of Point-of-Care Sofia® SARS Antigen Test for COVID-19 to Include Either Nasal or Nasopharyngeal Swabs
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that labeling for
Puma Biotechnology Announces Publication of Interim Results of Phase II CONTROL Trial in Annals of Oncology
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the publication of interim results from its Phase II CONTROL trial of neratinib in the September 2020 Issue (Volume
Momenta Pharmaceuticals: Nächste Mega-Übernahme im US-Biotechsektor!
Zuletzt verging kaum ein Tag, an dem nicht irgendeine Mega-Übernahme im US-Biotechsektor vermeldet wurde. So auch heute. Denn heute verkündete Johnson & Johnson die Übernahme von Momenta
True Leaf schließt Vereinbarung über den Verkauf von True Leaf Pet Inc. ab
Vernon (British Columbia), 19. August 2020. True Leaf Brands Inc. (CSE: MJ) (OTCQX: TRLFF) (FWB: TLA) („True Leaf“) gibt heute bekannt, dass True Leaf Pet Inc. („TLP“) im Rahmen des
True Leaf Enters into Asset Purchase Agreement to Sell True Leaf Pet Inc.
Vernon, BC - August 19, 2020 - True Leaf Brands Inc. (CSE: MJ) (OTC Pink: TRLFF) (FSE: TLA) (“True Leaf”) announced today that, as part of the sales process approved by Order of the British
Relay Medical and Fio Corporation Announce Joint Venture for Pandemic Testing Technology
August 19, 2020 – Relay Medical Corp. (“Relay” or the “Company”) (CSE: RELA, OTC: RYMDF, Frankfurt: EIY2), and Fio Corporation (“Fio”) are pleased to announce the establishment of a joint
Relay Medical und Fio Corporation gründen Joint Venture für Pandemie-Testmethode
19. August 2018 – Relay Medical Corp. („Relay“ oder das „Unternehmen“) (CSE: RELA, OTC: RYMDF, Frankfurt: EIY2) und Fio Corporation („Fio“) freuen sich, die Gründung eines Joint Ventures („J
Agilent Reports Third-Quarter Fiscal Year 2020 Financial Results
Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.26 billion for the third quarter ended July 31, 2020, a decline of 1% compared to the third quarter of 2019 and down 3.1% on a core(
QIAGEN bestärkt COVID-19-Forschung mit integrierten Coronavirus-NGS- und Software-Lösungen
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat das innovative QIAseq-SARS-CoV-2-Primer-Panel für Next-Generation-Sequencing (NGS) des Genoms des neuartigen Coronavirus sowie integrierte
QIAGEN Expands Integrated Coronavirus NGS and Software Solutions to Accelerate COVID-19 Research
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) launched the innovative QIAseq SARS-CoV-2 Primer Panel for next-generation sequencing (NGS) of the novel coronavirus genome, along with integrated
Premier Inc. Working with AstraZeneca to Reduce Hospitalizations of Patients with Hyperkalemia
Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, announced today it has reached a significant milestone in its partnership with AstraZeneca, a global, science-led